Thursday, 20 January, 2022
HomeA FocusNSAIDs could prevent onset of Alzheimer's — Canadian study

NSAIDs could prevent onset of Alzheimer's — Canadian study

AlzheimersOnce identified, those at risk of Alzheimer's disease can prevent disease development through self treatment by consumption of non-steroidal anti-inflammatory drugs (NSAIDs), adhering to a Mediterranean diet, and consuming antioxidants such as quercitin which is contained in coffee, according to Canadian research.

A Vancouver-based research team led by Canada's most cited neuro-scientist, Dr Patrick McGeer, has successfully carried out studies suggesting that, if started early enough, a daily regimen of the non-prescription NSAID (nonsteroidal anti-inflammatory drug) ibuprofen can prevent the onset of Alzheimer's disease. This means that by taking an over-the-counter medication, people can ward off a disease that, according to Alzheimer's Disease International's World Alzheimer Report 2016, affects an estimated 47m people worldwide, costs health care systems worldwide more than $818bn per year and is the fifth leading cause of death in those aged 65 or older.

The Alzheimer's Association estimates that there are more than 5m cases in the US alone, with a new case being identified every 66 seconds. The annual cost to the country in 2017 is estimated have been $259bn, with that figure predicted to potentially rise to $1.1trn by 2050.

McGeer, who is president and CEO of Vancouver-based Aurin Biotech, and his wife, Dr Edith McGeer, are among the most cited neuro-scientists in the world. Their laboratory is world-renowned for their 30 years of work in neuro-inflammation and neuro-degenerative diseases, particularly Alzheimer's disease.

In 2016, McGeer and his team announced that they had developed a simple saliva test that can diagnose Alzheimer's disease, as well as predict its future onset. The test is based on measuring the concentration of the peptide amyloid beta protein 42 (Abeta42) secreted in saliva. In most individuals, the rate of Abeta 42 production is almost exactly the same regardless of sex or age. However, if that rate of production is two to three times higher, those individuals are destined to develop Alzheimer's disease. That is because Abeta42 is a relatively insoluble material, and although it is made everywhere in the body, deposits of it occur only in the brain, causing neuro-inflammation, which destroys neurons in the brains of people with Alzheimer's disease.

Contrary to the widely held belief that Abeta 42 is made only in the brain, McGeer's team demonstrated that the peptide is made in all organs of the body and is secreted in saliva from the submandibular gland. As a result, with as little as one teaspoon of saliva, it is possible to predict whether an individual is destined to develop Alzheimer's disease. This gives them an opportunity to begin taking early preventive measures such as consuming non-prescription non-steroidal drugs (NSAIDs) such as ibuprofen.

"What we've learned through our research is that people who are at risk of developing Alzheimer's exhibit the same elevated Abeta 42 levels as people who already have it; moreover, they exhibit those elevated levels throughout their lifetime so, theoretically, they could get tested anytime," says McGeer. "Knowing that the prevalence of clinical Alzheimer's disease commences at age 65, we recommend that people get tested ten years before, at age 55, when the onset of Alzheimer's would typically begin. If they exhibit elevated Abeta 42 levels then, that is the time to begin taking daily ibuprofen to ward off the disease.

"Unfortunately, most clinical trials to date have focused on patients whose cognitive deficits are already mild to severe, and when the therapeutic opportunities in this late stage of the disease are minimal. Consequently, every therapeutic trial has failed to arrest the disease's progression. Our discovery is a game changer. We now have a simple test that can indicate if a person is fated to develop Alzheimer's disease long before it begins to develop. Individuals can prevent that from happening through a simple solution that requires no prescription or visit to a doctor. This is a true breakthrough since it points in a direction where AD can eventually be eliminated."

The means are now at hand to conquer Alzheimer’s disease (AD). The method is to identify those at risk for the disease before clinical signs develop. That is followed by implementing measures that can effectively prevent disease development. Since biotechnology markers have shown that AD commences at least a decade before cognitive deficits set in, there is an extended window of opportunity to successfully prevent disease development. Methods of identifying those at risk include positron electron microscopy for AD senile plaques, blood or saliva analysis for elevation of the amyloid-β protein fragment terminating at position 42, and cerebrospinal fluid analysis showing a decrease in content of this protein. Of the modalities available, saliva is by far the simplest and least invasive. Once identified, those at risk can prevent disease development through self treatment by consumption of non-steroidal anti-inflammatory drugs, adhering to a Mediterranean diet, and consuming antioxidants such as quercitin which is contained in coffee.

Patrick L McGeer, Edith McGeer

[link url=""]IOS Press material[/link]
[link url=""]Journal of Alzheimer’s Disease abstract[/link]

MedicalBrief — our free weekly e-newsletter

We'd appeciate as much information as possible, however only an email address is required.